Research & Literature

Effect of postural changes on aldosterone to plasma renin ratio in patients with suspected secondary hypertension.

Barigou M, Ah-Kang F, Orloff E, et al.

Annales de cardiologie et d'angeiologie 2015; (64(3)):169-74.

A renin-ssance in primary aldosteronism testing: obstacles and opportunities for screening, diagnosis, and management.

Raizman JE, Diamandis EP, Holmes D, et al.

Clinical chemistry 2015; (61(8)):1022-7 doi:10.1373/clinchem.2015.242990.

Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands.

Nishimoto K, Tomlins SA, Kuick R, et al.

Proceedings of the National Academy of Sciences of the United States of America 2015; (112(33)):E4591-9 doi:10.1073/pnas.1505529112.

Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype.

Scholl UI, Healy JM, Thiel A, et al.

Clinical endocrinology 2015; (83(6)):779-89 doi:10.1111/cen.12873.

Novel somatic mutations and distinct molecular signature in aldosterone-producing adenomas.

Åkerström T, Willenberg HS, Cupisti K, et al.

Endocrine-related cancer 2015; (22(5)):735-44 doi:10.1530/ERC-15-0321.

Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.

Lainscak M, Pelliccia F, Rosano G, et al.

International journal of cardiology 2015; (200()):25-9.

Use of plasma metanephrine to aid adrenal venous sampling in combined aldosterone and cortisol over-secretion.

Goupil R, Wolley M, Ungerer J, et al.

Endocrinology, diabetes & metabolism case reports 2015; (2015()):150075 doi:10.1530/EDM-15-0075.

The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.

Funder JW, Carey RM, Mantero F, et al.

The Journal of clinical endocrinology and metabolism 2016; (101(5)):1889-916 doi:10.1210/jc.2015-4061.

Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.

Sica DA

Methodist DeBakey cardiovascular journal 2015; (11(4)):235-9 doi:10.14797/mdcj-11-4-235.

SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook.

Amar L, Baguet JP, Bardet S, et al.

Annales d'endocrinologie 2016; (77(3)):179-86.

Effect of Moxonidine on the Aldosterone/Renin Ratio in Healthy Male Volunteers.

Ahmed AH, Gordon RD, Ward G, et al.

The Journal of clinical endocrinology and metabolism 2017; (102(6)):2039-2043 doi:10.1210/jc.2016-3821.

Quantitative Value of Aldosterone-Renin Ratio for Detection of Aldosterone-Producing Adenoma: The Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) Study.

Maiolino G, Rossitto G, Bisogni V, et al.

Journal of the American Heart Association 2017; (6(5)) doi:10.1161/JAHA.117.005574.

Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort.

Williams TA, Lenders JWM, Mulatero P, et al.

The lancet. Diabetes & endocrinology 2017; (5(9)):689-699 doi:10.1016/S2213-8587(17)30135-3.

Aldosterone in Advancing Age: Don't Shoot the Messenger.

Funder JW

Circulation 2017; (136(4)):356-358 doi:10.1161/CIRCULATIONAHA.117.029421.

Adrenal venous sampling for primary aldosteronism: laboratory medicine best practice.

Kline G, Holmes DT

Journal of clinical pathology 2017; (70(11)):911-916 doi:10.1136/jclinpath-2017-204423.

Aldosterone to Renin Ratio as a Screening Instrument for Primary Aldosteronism in a Middle-Aged Population with Atrial Fibrillation.

Mourtzinis G, Ebrahimi A, Gustafsson H, et al.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2017; (49(11)):831-837 doi:10.1055/s-0043-119220.

The Potential Role of Primary Care in Case Detection/Screening of Primary Aldosteronism.

Kline GA, Prebtani APH, Leung AA, Schiffrin EL

American journal of hypertension 2017; (30(12)):1147-1150 doi:10.1093/ajh/hpx064.

Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.

Monticone S, D'Ascenzo F, Moretti C, et al.

The lancet. Diabetes & endocrinology 2018; (6(1)):41-50 doi:10.1016/S2213-8587(17)30319-4.

Health-Related Quality of Life and Mental Health in Primary Aldosteronism: A Systematic Review.

Velema MS, de Nooijer AH, Burgers VWG, et al.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2017; (49(12)):943-950 doi:10.1055/s-0043-121706.

Aldosterone-Producing Cell Clusters in Normal and Pathological States.

Omata K, Tomlins SA, Rainey WE

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2017; (49(12)):951-956 doi:10.1055/s-0043-122394.

GENETICS IN ENDOCRINOLOGY: The expanding genetic horizon of primary aldosteronism.

Monticone S, Buffolo F, Tetti M, et al.

European journal of endocrinology 2018; (178(3)):R101-R111.

Case detection in primary aldosteronism: high-diagnostic value of the aldosterone-to-renin ratio when performed under standardized conditions.

Vorselaars WMCM, Valk GD, Vriens MR, et al.

Journal of hypertension 2018; (36(7)):1585-1591 doi:10.1097/HJH.0000000000001718.

Saline suppression test parameters may predict bilateral subtypes of primary aldosteronism.

Hashimura H, Shen J, Fuller PJ, et al.

Clinical endocrinology 2018; (89(3)):308-313 doi:10.1111/cen.13757.

Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.

Hundemer GL, Curhan GC, Yozamp N, et al.

Hypertension (Dallas, Tex. : 1979) 2018; (72(3)):658-666 doi:10.1161/HYPERTENSIONAHA.118.11568.

Is it time to screen all patients with hypertension for primary aldosteronism?

Yang J, Fuller PJ, Stowasser M

The Medical journal of Australia 2018; (209(2)):57-59 doi:10.5694/mja17.00783.

Factors Associated with Resolution of Hypertension after Adrenalectomy in Patients with Primary Aldosteronism.

Loh WJ, Lim DST, Loh LM, Kek PC

Endocrinology and metabolism (Seoul, Korea) 2018; (33(3)):355-363 doi:10.3803/EnM.2018.33.3.355.

Cortisol Excess in Patients With Primary Aldosteronism Impacts Left Ventricular Hypertrophy.

Adolf C, Köhler A, Franke A, et al.

The Journal of clinical endocrinology and metabolism 2018; (103(12)):4543-4552 doi:10.1210/jc.2018-00617.

Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism.

Ohno Y, Sone M, Inagaki N, et al.

The Journal of clinical endocrinology and metabolism 2018; (103(12)):4456-4464 doi:10.1210/jc.2018-00866.

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Carey RM, Calhoun DA, Bakris GL, et al.

Hypertension (Dallas, Tex. : 1979) 2018; (72(5)):e53-e90 doi:10.1161/HYP.0000000000000084.

A novel clinical nomogram to predict bilateral hyperaldosteronism in Chinese patients with primary aldosteronism.

Xiao L, Jiang Y, Zhang C, et al.

Clinical endocrinology 2019; (90(6)):781-788 doi:10.1111/cen.13962.

Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?

Manolis AA, Manolis TA, Melita H, Manolis AS

Current hypertension reports 2019; (21(3)):22 doi:10.1007/s11906-019-0924-0.

Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.

Stavropoulos K, Papadopoulos C, Koutsampasopoulos K, et al.

Current pharmaceutical design 2018; (24(46)):5508-5516 doi:10.2174/1381612825666190311130138.

Success rate of adrenal venous sampling and predictors for success: a retrospective study.

Chayovan T, Limumpornpetch P, Hongsakul K

Polish journal of radiology 2019; (84()):e136-e141 doi:10.5114/pjr.2019.84178.

Clinical outcomes after surgery for primary aldosteronism: Evaluation of the PASO-investigators' consensus criteria within a worldwide cohort of patients.

Vorselaars WMCM, van Beek DJ, Postma EL, et al.

Surgery 2019; (166(1)):61-68 doi:10.1016/j.surg.2019.01.031.

Effect of unilateral adrenalectomy on the quality of life of patients with lateralized primary aldosteronism.

Citton M, Viel G, Torresan F, et al.

BMC surgery 2019; (18(Suppl 1)):105 doi:10.1186/s12893-018-0432-1.

Renal damage in primary aldosteronism: a systematic review and meta-analysis.

Monticone S, Sconfienza E, D'Ascenzo F, et al.

Journal of hypertension 2020; (38(1)):3-12 doi:10.1097/HJH.0000000000002216.

A combination of captopril challenge test after saline infusion test improves diagnostic accuracy for primary aldosteronism.

Lin C, Yang J, Fuller PJ, et al.

Clinical endocrinology 2020; (92(2)):131-137 doi:10.1111/cen.14134.

Atrial fibrillation as presenting sign of primary aldosteronism: results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) Study.

Seccia TM, Letizia C, Muiesan ML, et al.

Journal of hypertension 2020; (38(2)):332-339 doi:10.1097/HJH.0000000000002250.

Persistent severe hyperkalemia following surgical treatment of aldosterone-producing adenoma.

Preda C, Teodoriu LC, Placinta S, et al.

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 2020; (25()):17 doi:10.4103/jrms.JRMS_603_19.

New advances in the diagnosis of primary aldosteronism.

Shen H, Xu ZX, Li QF

Chronic diseases and translational medicine 2020; (6(1)):1-5 doi:10.1016/j.cdtm.2019.12.009.

Primary Aldosteronism in Patients in China With Recently Detected Hypertension.

Xu Z, Yang J, Hu J, et al.

Journal of the American College of Cardiology 2020; (75(16)):1913-1922 doi:10.1016/j.jacc.2020.02.052.

The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study.

Brown JM, Siddiqui M, Calhoun DA, et al.

Annals of internal medicine 2020; (173(1)):10-20 doi:10.7326/M20-0065.

Evolution of the Primary Aldosteronism Syndrome: Updating the Approach.

Vaidya A, Carey RM

The Journal of clinical endocrinology and metabolism 2020; (105(12)) doi:10.1210/clinem/dgaa606.

Long-term outcome success after operative treatment for primary aldosteronism.

Picado O, Whitfield BW, Khan ZF, et al.

Surgery 2021; (169(3)):528-532 doi:10.1016/j.surg.2020.07.046.

Update: Selective adrenal venous sampling (AVS) - Indication, technique, and significance.

Loberg C, Antoch G, Stegbauer J, et al.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2021; (193(6)):658-666 doi:10.1055/a-1299-1878.

Development of a Prediction Score to Avoid Confirmatory Testing in Patients With Suspected Primary Aldosteronism.

Burrello J, Amongero M, Buffolo F, et al.

The Journal of clinical endocrinology and metabolism 2021; (106(4)):e1708-e1716 doi:10.1210/clinem/dgaa974.

The effect of medication on the aldosterone-to-renin ratio. A critical review of the literature.

Alnazer RM, Veldhuizen GP, Kroon AA, de Leeuw PW

Journal of clinical hypertension (Greenwich, Conn.) 2021; (23(2)):208-214 doi:10.1111/jch.14173.

Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.

Tezuka Y, Turcu AF

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(12)):1416-1424 doi:10.4158/EP-2020-0277.

ASO Author Reflections: Predicting Postoperative Resolution of Hypertension in Primary Hyperaldosteronism.

Chatani PD, Dominguez DA, Nilubol N

Annals of surgical oncology 2021; (28(12)):7496 doi:10.1245/s10434-021-09762-w.

Differential effects of reduced mineralocorticoid receptor activation by unilateral adrenalectomy vs mineralocorticoid antagonist treatment in patients with primary aldosteronism - Implications for depression and anxiety.

Murck H, Adolf C, Schneider A, et al.

Journal of psychiatric research 2021; (137()):376-382 doi:10.1016/j.jpsychires.2021.02.064.

Functional Characteristic and Significance of Aldosterone-Producing Cell Clusters in Primary Aldosteronism and Age-Related Hypertension.

Pauzi FA, Azizan EA

Frontiers in endocrinology 2021; (12()):631848 doi:10.3389/fendo.2021.631848.

Prospective Screening for Primary Aldosteronism in Patients With Suspected Obstructive Sleep Apnea.

Chee MR, Hoo J, Libianto R, et al.

Hypertension (Dallas, Tex. : 1979) 2021; (77(6)):2094-2103 doi:10.1161/HYPERTENSIONAHA.120.16902.

Pathology of Aldosterone Biosynthesis and its Action.

Gao X, Yamazaki Y, Tezuka Y, et al.

The Tohoku journal of experimental medicine 2021; (254(1)):1-15 doi:10.1620/tjem.254.1.

Re-evaluating absent clinical success after adrenalectomy in unilateral primary aldosteronism.

Chan YHB, Loh LM, Foo RS, et al.

Surgery 2021; (170(5)):1389-1396 doi:10.1016/j.surg.2021.05.038.

Primary Aldosteronism: a Continuum from Normotension to Hypertension.

Wannachalee T, Turcu AF

Current cardiology reports 2021; (23(8)):105 doi:10.1007/s11886-021-01538-8.

Improvement in quality of life and psychological symptoms after treatment for primary aldosteronism: Asian Cohort Study.

Tan YK, Kwan YH, Teo DCL, et al.

Endocrine connections 2021; (10(8)):834-844.

Screening for Primary Aldosteronism is Underutilized in Patients with Obstructive Sleep Apnea.

Conroy PC, Hernandez S, Graves CE, et al.

The American journal of medicine 2022; (135(1)):60-66 doi:10.1016/j.amjmed.2021.07.041.

The Effects of Verapamil, Hydralazine, and Doxazosin on Renin, Aldosterone, and the Ratio Thereof.

Veldhuizen GP, Alnazer RM, de Leeuw PW, Kroon AA

Cardiovascular drugs and therapy 2023; (37(2)):283-289 doi:10.1007/s10557-021-07262-3.

Diagnosis and treatment of primary aldosteronism.

Reincke M, Bancos I, Mulatero P, et al.

The lancet. Diabetes & endocrinology 2021; (9(12)):876-892 doi:10.1016/S2213-8587(21)00210-2.

Screening for primary aldosteronism in the diabetic population: a cohort study.

Tan SJ, Libianto R, Yang J, Wong J

Internal medicine journal 2023; (53(5)):709-716 doi:10.1111/imj.15690.

Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism.

Lin X, Ullah MHE, Wu X, et al.

Frontiers in cardiovascular medicine 2021; (8()):798364 doi:10.3389/fcvm.2021.798364.

Screening for primary aldosteronism is underutilised in patients with chronic kidney disease.

Chauhan K, Schachna E, Libianto R, et al.

Journal of nephrology 2022; (35(6)):1667-1677 doi:10.1007/s40620-022-01267-3.

Re-Assessment of the Oral Salt Loading Test Using a New Chemiluminescent Enzyme Immunoassay Based on a Two-Step Sandwich Method to Measure 24-Hour Urine Aldosterone Excretion.

Ozeki Y, Kinoshita M, Miyamoto S, et al.

Frontiers in endocrinology 2022; (13()):859347 doi:10.3389/fendo.2022.859347.

Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021.

Naruse M, Katabami T, Shibata H, et al.

Endocrine journal 2022; (69(4)):327-359 doi:10.1507/endocrj.EJ21-0508.

Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study.

Brown JM, Wijkman MO, Claggett BL, et al.

Hypertension (Dallas, Tex. : 1979) 2022; (79(9)):1984-1993 doi:10.1161/HYPERTENSIONAHA.122.19134.

Performance of Confirmatory Tests for Diagnosing Primary Aldosteronism: a Systematic Review and Meta-Analysis.

Leung AA, Symonds CJ, Hundemer GL, et al.

Hypertension (Dallas, Tex. : 1979) 2022; (79(8)):1835-1844 doi:10.1161/HYPERTENSIONAHA.122.19377.

Prevalence and clinical characteristics of primary aldosteronism in a tertiary-care center in Korea.

Yoon M, Hong N, Ha J, et al.

Hypertension research : official journal of the Japanese Society of Hypertension 2022; (45(9)):1418-1429 doi:10.1038/s41440-022-00948-7.

Aldosterone as a Mediator of Cardiovascular Damage.

Buffolo F, Tetti M, Mulatero P, Monticone S

Hypertension (Dallas, Tex. : 1979) 2022; (79(9)):1899-1911 doi:10.1161/HYPERTENSIONAHA.122.17964.

Primary Aldosteronism: State-of-the-Art Review.

Vaidya A, Hundemer GL, Nanba K, et al.

American journal of hypertension 2022; (35(12)):967-988 doi:10.1093/ajh/hpac079.

Development and validation of model for sparing adrenal venous sampling in diagnosing unilateral primary aldosteronism.

Song Y, Yang J, Shen H, et al.

Journal of hypertension 2022; (40(9)):1692-1701 doi:10.1097/HJH.0000000000003197.

Primary aldosteronism - a multidimensional syndrome.

Turcu AF, Yang J, Vaidya A

Nature reviews. Endocrinology 2022; (18(11)):665-682 doi:10.1038/s41574-022-00730-2.

Stroke Risks in Primary Aldosteronism with Different Treatments: A Systematic Review and Meta-Analysis.

Qian N, Xu J, Wang Y

Journal of cardiovascular development and disease 2022; (9(9)) doi:10.3390/jcdd9090300.

Differential central regulatory mineralocorticoidreceptor systems for anxiety and depression - Could KCNJ5 be an interesting target for further investigations in major depression?

Adolf C, Murck H, Sarkis AL, et al.

Journal of psychiatric research 2022; (156()):69-77 doi:10.1016/j.jpsychires.2022.09.008.

Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.

Freeman MW, Bond M, Murphy B, et al.

Hypertension research : official journal of the Japanese Society of Hypertension 2023; (46(1)):108-118 doi:10.1038/s41440-022-01070-4.

Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis.

Chen SY, Chen JY, Huang WC, et al.

European journal of endocrinology 2022; (187(6)):S47-S58 doi:10.1530/EJE-22-0375.

Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.

Freeman MW, Halvorsen YD, Marshall W, et al.

The New England journal of medicine 2023; (388(5)):395-405 doi:10.1056/NEJMoa2213169.

Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.

Wu VC, Chan CK, Chueh JS, et al.

Journal of the American Heart Association 2023; (12(4)):e028146 doi:10.1161/JAHA.122.028146.

The Adrenal Vein Sampling Outcomes Study (AVOS): success rates following adrenalectomy for unilateral primary aldosteronism.

Sawyer N, Glendenning P, Vasikaran SD, et al.

Pathology 2023; (55(4)):531-537 doi:10.1016/j.pathol.2023.02.002.

Aldosterone: Essential for Life but Damaging to the Vascular Endothelium.

Crompton M, Skinner LJ, Satchell SC, Butler MJ

Biomolecules 2023; (13(6)) doi:10.3390/biom13061004.

Using plasma aldosterone concentrations at 1 h of saline infusion test for the diagnosis of primary aldosteronism.

Phonanuwong R, Jannoo S, Chanthanuwat S, Soonthornpun S

Journal of hypertension 2023; (41(9)):1493-1497 doi:10.1097/HJH.0000000000003504.

Association of Reversal of Renin Suppression With Long-Term Renal Outcome in Medically Treated Primary Aldosteronism.

Katsuragawa S, Goto A, Shinoda S, et al.

Hypertension (Dallas, Tex. : 1979) 2023; (80(9)):1909-1920 doi:10.1161/HYPERTENSIONAHA.123.21096.

The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism.

Zheng Y, Long T, Peng N, et al.

The Journal of clinical endocrinology and metabolism 2023; (109(1)):171-182 doi:10.1210/clinem/dgad421.

Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease.

Bayne S, LeFevre J, Olstinske K, et al.

Advanced biology 2024; (8(3)):e2300496 doi:10.1002/adbi.202300496.

Reversal of arterial stiffness in medically and surgically treated unilateral primary aldosteronism.

Chen ZW, Liao CW, Pan CT, et al.

Journal of hypertension 2024; (42(3)):538-545 doi:10.1097/HJH.0000000000003631.

Clinical and biochemical outcomes after adrenalectomy for primary aldosteronism in tertiary and quaternary referral centers: data from SOPRANO study.

Marzano L, Ronco C

Hypertension research : official journal of the Japanese Society of Hypertension 2024; (47(3)):721-734 doi:10.1038/s41440-023-01554-x.

Update on Primary Aldosteronism: Time to Screen All Hypertensives.

Memon SS, Bandgar T

The Journal of the Association of Physicians of India 2024; (72(1)):11-12 doi:10.59556/japi.71.0430.

Sparing confirmatory testing in primary aldosteronism (SCIPA): a multicenter retrospective diagnostic accuracy study.

Ong Lopez AMC, Tiu LE, Dimayuga DC, et al.

BMC endocrine disorders 2024; (24(1)):105 doi:10.1186/s12902-024-01638-w.

Comparing ARR Versus Suppressed PRA as Screening Tests for Primary Aldosteronism.

Marcelli M, Bi C, Funder JW, McPhaul MJ

Hypertension (Dallas, Tex. : 1979) 2024; (81(10)):2072-2081 doi:10.1161/HYPERTENSIONAHA.124.22884.

Impact of primary aldosteronism on kidney function: results from the SPAIN-ALDO registry.

Araujo-Castro M, Paja Fano M, González-Boillos M, et al.

Journal of hypertension 2024; (42(10)):1805-1812 doi:10.1097/HJH.0000000000003813.

Primary aldosteronism prevalence enhanced by strict adherence to 2016 Endocrine Society guidelines: insights from an endocrine hypertension unit.

Ruiz-Sanchez JG, Fernandez Sanchez Á, Cardenas-Salas J, et al.

Journal of hypertension 2024; (42(10)):1813-1822 doi:10.1097/HJH.0000000000003822.

Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis.

Elshahat A, Mansour A, Ellabban M, et al.

BMC cardiovascular disorders 2024; (24(1)):489 doi:10.1186/s12872-024-04103-7.

Mineralocorticoid receptor antagonist monotherapy in pediatric non-classical 11β-hydroxylase deficiency.

Kennedy EC, Stack M, Carolan E, et al.

Journal of pediatric endocrinology & metabolism : JPEM 2024; (37(12)):1100-1103 doi:10.1515/jpem-2024-0194.

Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort.

Yang J, Burrello J, Goi J, et al.

The lancet. Diabetes & endocrinology 2025; (13(2)):119-133 doi:10.1016/S2213-8587(24)00308-5.

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta-Analysis.

Huang CW, Huang TY, Yang YF, et al.

Journal of the American Heart Association 2025; (14(3)):e038714 doi:10.1161/JAHA.124.038714.

Breaking down resistance: novel aldosterone synthase inhibitors in the management of resistant hypertension.

Eddison Chung Hung C, Kocherry C, George J

Journal of hypertension 2025; (43(8)):1286-1295 doi:10.1097/HJH.0000000000004055.

Initial experience with adrenal vein sampling using 3D cursor and preprocedural computed tomography (CT) scout image.

Kim MS, Hong HP, Park CY, et al.

Clinical radiology 2025; (86()):106928 doi:10.1016/j.crad.2025.106928.

Clinical diagnosis and treatment of a patient with hypertension, hypokalemia, and bilateral adrenal adenomas.

Zhang T, Chen T, Zhang W, et al.

Frontiers in endocrinology 2025; (16()):1558841 doi:10.3389/fendo.2025.1558841.

Adrenalectomy Versus Medical Therapy in Primary Aldosteronism: A Meta-Analysis of Long-Term Cardiac Remodeling and Function: Medical versus Adrenalectomy Treatment Compared in Hyperaldosteronism (MATCH) Study.

Marzano L, Zoccatelli F, Pizzolo F, Friso S

Hypertension (Dallas, Tex. : 1979) 2025; (82(8)):e142-e153 doi:10.1161/HYPERTENSIONAHA.125.25104.

Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.

Saxena M, Laffin L, Borghi C, et al.

JAMA 2025; (334(5)):409-418 doi:10.1001/jama.2025.9413.

Title not available

Hibatouallah H, Guedira MM, Siagh S, et al.

Annales de cardiologie et d'angeiologie 2025; (74(5)):101952 doi:10.1016/j.ancard.2025.101952.

Renal function after adrenalectomy in patients with primary aldosteronism.

Stahl KA, Ramonell KM, Puli A, et al.

Surgery 2026; (189()):109761 doi:10.1016/j.surg.2025.109761.

Diagnostic Challenges of Adrenal Venous Sampling for Primary Hyperaldosteronism in a Patient With Subclinical Cushing's Syndrome: A Case Report.

Malekian M, Sadra V, Bahrami A, et al.

Clinical case reports 2025; (13(12)):e71578 doi:10.1002/ccr3.71578.

Hypertensive crisis due to secondary aldosteronism from polyarteritis nodosa.

Liu Y, Gong JY, Sydenham-Clarke LM, et al.

BMJ case reports 2026; (19(1)) doi:10.1136/bcr-2025-269055.

The adrenal gland and primary aldosteronism: anatomy, steroidogenesis, regulation, and genetic insights.

Long KC, Azizan EA

Frontiers in endocrinology 2025; (16()):1736534 doi:10.3389/fendo.2025.1736534.

Identification of Aldosterone-Producing Adrenal Adenomas Using [68Ga]Ga-Pentixafor PET/CT in an Australian Cohort.

Ng E, Jong I, Lau KK, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2026; (67(4)):606-614 doi:10.2967/jnumed.125.271006.

Aldosterone-mineralocorticoid receptor interactions: new insights and therapeutic perspectives in primary aldosteronism.

Yoshida Y, Shibata H

Hypertension research : official journal of the Japanese Society of Hypertension 2026; (49(4)):1336-1342 doi:10.1038/s41440-026-02561-4.

Pathogenesis of primary aldosteronism.

Parra Ramírez P, Martín Rojas-Marcos P

Vitamins and hormones 2026; (130()):27-41 doi:10.1016/bs.vh.2025.08.004.

Prevalence of primary aldosteronism and screening indications.

Ruiz-Sanchez JG

Vitamins and hormones 2026; (130()):43-67 doi:10.1016/bs.vh.2025.08.001.

Aldosterone synthase inhibitors for resistant or uncontrolled hypertension: a network meta-analysis of randomized clinical trials.

Elbahloul MA, Ali AHG, Al-Shammari AS, et al.

Journal of hypertension 2026; (44(4)):542-552 doi:10.1097/HJH.0000000000004264.

Pooled diagnostic accuracy of 68Ga-pentixafor PET/CT for aldosterone-producing lesions in primary aldosteronism.

Ohannesian VA, Rajchenberg D, Menezes IR, et al.

Clinical imaging 2026; (131()):110743 doi:10.1016/j.clinimag.2026.110743.

Concomitant Enalapril and Spironolactone-Induced Hyperkalemia in a Pediatric Patient.

Rogado SM, Pinto JM, Hernandez LC, et al.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 2026; (31(1)):83-87 doi:10.5863/JPPT-25-00009.

Biochemical success after selective adrenal arterial embolization predicts long-term regression of aldosterone-mediated cardiac remodeling.

Shuai WL, Zhang HC, Xiong HL, et al.

American journal of hypertension 2026; (39(9)):1132-1141 doi:10.1093/ajh/hpag015.

Aldosterone and Impaired Nocturnal Blood Pressure Decline in Primary Aldosteronism.

Liang NP, Li N, Wu H, et al.

Journal of the American Heart Association 2026; (15(6)):e044976 doi:10.1161/JAHA.125.044976.

68Ga-Pentixafor PET/CT for diagnosing surgically curable primary aldosteronism concurrent with autonomous cortisol secretion.

Jiang Y, Zhang X, Zeng Q, et al.

Journal of hypertension 2026; (44(7)):1221-1229 doi:10.1097/HJH.0000000000004319.

Targeting the untargeted: Molecular insights and emerging therapeutic strategies for primary aldosteronism.

Lu H, Zhang Y, Qiu D, et al.

European journal of pharmacology 2026; (1029()):179035 doi:10.1016/j.ejphar.2026.179035.

Predictors of treatment response to mineralocorticoid receptor antagonists in primary aldosteronism: insights from the SPAIN-ALDO registry.

Goi J, Paja Fano M, Rizo Gellida A, et al.

Journal of hypertension 2026; (44(9)):1530-1538 doi:10.1097/HJH.0000000000004365.

Biochemical and clinical remission after adrenalectomy in patients with primary aldosteronism: a retrospective two-center study.

Matthey Giè ML, St-Amour P, Karenovics W, et al.

Gland surgery 2026; (15(5)):137 doi:10.21037/gs-2026-1-0087.

The Lingering Battle of Persistent Hypoaldosteronism Following Adrenalectomy for Primary Aldosteronism: A Case Report.

En Tan J, Merican NSYA, Ismail S, Abdullah NRA

Journal of the ASEAN Federation of Endocrine Societies 2026; (41(1)):198-203 doi:10.15605/jafes.041.01.5151.